224 related articles for article (PubMed ID: 28906155)
1. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review.
Mercadante S
Curr Med Res Opin; 2017 Nov; 33(11):1965-1969. PubMed ID: 28906155
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
[TBL] [Abstract][Full Text] [Related]
3. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.
Mercadante S; Porzio G; Aielli F; Adile C; Verna L; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):661-6. PubMed ID: 23540512
[TBL] [Abstract][Full Text] [Related]
4. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
5. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
[TBL] [Abstract][Full Text] [Related]
6. Tapentadol for Cancer Pain Management: A Narrative Review.
Carmona-Bayonas A; Jiménez Fonseca P; Virizuela Echaburu J
Pain Pract; 2017 Nov; 17(8):1075-1088. PubMed ID: 28084045
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
9. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
Sazuka S; Koitabashi T
J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
[TBL] [Abstract][Full Text] [Related]
12. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
14. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of tapentadol in chronic severe pain.
Riemsma R; Forbes C; Harker J; Worthy G; Misso K; Schäfer M; Kleijnen J; Stürzebecher S
Curr Med Res Opin; 2011 Oct; 27(10):1907-30. PubMed ID: 21905968
[TBL] [Abstract][Full Text] [Related]
16. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
17. Tapentadol for the management of cancer pain in adults: an update.
Boland JW
Curr Opin Support Palliat Care; 2023 Jun; 17(2):90-97. PubMed ID: 36919687
[TBL] [Abstract][Full Text] [Related]
18. Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan.
Chen YJ; Chiang CC; Huang PJ; Huang J; Karcher K; Li H
Curr Med Res Opin; 2015 Nov; 31(11):2001-9. PubMed ID: 26293513
[TBL] [Abstract][Full Text] [Related]
19. [Sustained-release Opioids: Morphine, Oxycodone and Tapentadol].
Takahashi Y; Iseki M
Masui; 2015 Nov; 64(11):1133-40. PubMed ID: 26689063
[TBL] [Abstract][Full Text] [Related]
20. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
